⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoramidic Acid SCHEMBL28135205 | 0.78 | CA2 (0.46) | — | |
| SCHEMBL224758 | 0.78 | — | — | |
| Phosphoramidic Acid SCHEMBL25846 | 0.78 | — | — | |
| Diamidophosphate SCHEMBL43115 | 0.78 | — | — | |
| SCHEMBL440940 | 0.78 | — | — | |
| Phosphoramidic Acid SCHEMBL30498012 | 0.78 | CA2 (0.46) | — | |
| SCHEMBL123363 | 0.78 | — | — | |
| SCHEMBL454419 | 0.78 | — | — | |
| SCHEMBL10889963 | 0.78 | — | — | |
| SCHEMBL3153854 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 530 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378267-B2 | Synthesis of FMOC-protected morpholino monomers and oligomers | ENTRADA THERAPEUTICS, INC. (US) | 2025-08-05 | — | — | US | claimed |
| US-20250171475-A1 | CHIRAL REAGENTS FOR PREPARATION OF HOMOGENEOUS OLIGOMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-05-29 | — | — | US | claimed |
| US-12012427-B2 | Synthesis of Fmoc-protected morpholino monomers and their use in the synthesis of morpholino oligomer | INDIAN ASSOCIATION FOR THE CULTIVATION OF SCIENCE (IN) | 2024-06-18 | — | — | US | claimed |
| US-20230097585-A1 | SYNTHESIS OF FMOC-PROTECTED MORPHOLINO MONOMERS AND OLIGOMERS | ENTRADA THERAPEUTICS, INC. | 2023-03-30 | — | — | US | claimed |
| CN-113754694-B | Method for synthesizing Reidesvir by asymmetric catalysis of non-protecting group nucleoside | 上海交通大学 | 2022-10-25 | — | — | CN | claimed |
| EP-3331891-B1 | A METHOD FOR PREPARING A SUBSTANTIALLY DIASTEREOMERICALLY PURE PHOSPHORODIAMIDATE OLIGOMER, A PHOSPHORODIAMIDATE OLIGOMER MADE BY SUCH A METHOD AND A PHARMACEUTICAL COMPOSITION COMPRISING SUCH A PHOSPHORODIAMIDATE OLIGOMER | EISAI R&D MAN CO LTD (JP) | 2021-12-15 | — | — | EP | claimed |
| CN-113461733-A | Chiral reagents for the preparation of homogeneous oligomers | 卫材R&D管理有限公司 | 2021-10-01 | — | — | CN | claimed |
| US-20210171555-A1 | CHIRAL REAGENTS FOR PREPARATION OF HOMOGENEOUS OLIGOMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-06-10 | — | — | US | claimed |
| US-20180222932-A1 | CHIRAL REAGENTS FOR PREPARATION OF HOMOGENEOUS OLIGOMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-08-09 | — | — | US | claimed |
| EP-3331891-A2 | CHIRAL REAGENTS FOR PREPARATION OF HOMOGENEOUS OLIGOMERS | Eisai R&D Management Co., Ltd. (JP) | 2018-06-13 | — | — | EP | claimed |
| WO-2017024264-A2 | CHIRAL REAGENTS FOR PREPARATION OF HOMOGENEOUS OLIGOMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-02-09 | — | — | WO | claimed |
| US-8076476-B2 | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits | AVI BIOPHARMA, INC. (US) | 2011-12-13 | — | — | US | claimed |
| EP-2207779-A1 | METHOD OF SYNTHESIS OF MORPHOLINO OLIGOMERS | Avi Biopharma, Inc. (US) | 2010-07-21 | — | — | EP | claimed |
| WO-2009064471-A1 | METHOD OF SYNTHESIS OF MORPHOLINO OLIGOMERS | AVI BIOPHARMA, INC. (US) | 2009-05-22 | — | — | WO | claimed |
| US-20090131624-A1 | SYNTHESIS OF MORPHOLINO OLIGOMERS USING DOUBLY PROTECTED GUANINE MORPHOLINO SUBUNITS | AVI BIOPHARMA, INC. (US) | 2009-05-21 | — | — | US | claimed |
| EP-1468007-A2 | PSEUDONUCLEOTIDE COMPRISING AN INTERCALATOR | Human Genetic Signatures PTY Ltd. (AU) | 2004-10-20 | — | — | EP | claimed |
| WO-2003051901-A2 | PSEUDONUCLEOTIDE COMPRISING AN INTERCALATOR | HUMAN GENETIC SIGNATURES PTY LTD (AU) | 2003-06-26 | — | — | WO | claimed |
| US-5114538-A | Treating cellulose fibers with cationic papermaking stock adding a reactive sizing agent, forming a web and reacting the size | EXXON CHEMICAL PATENTS INC. (US) | 1992-05-19 | — | — | US | claimed |
| EP-0320942-A2 | Novel polysaccharides novel macromolecular conjugates of the polysaccharides | AMERICAN CYANAMID COMPANY (US) | 1989-06-21 | — | — | EP | claimed |
| JP-1238594-A | — | — | None | — | — | JP | disclosed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-3448392-B1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260124226-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-04-16 | — | — | US | disclosed |
| US-12590306-B2 | Processes for preparing phosphorodiamidate morpholino oligomers via fast-flow synthesis | SAREPTA THERAPEUTICS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4705284-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | Emory University (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260053838-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING SUBSTITUTED NUCLEOTIDES AND NUCLEOSIDES FOR TREATING VIRAL INFECTIONS | UNIV EMORY (US) | 2026-02-26 | — | — | US | disclosed |
| US-12509466-B2 | Methods and compounds for treating paramyxoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250388619-A1 | VERSATILE SYNTHETIC ROUTE FOR NEUTRAL MORPHOLINO OLIGONUCLEOTIDES WITH PHOSPHORYL GUANIDINIUM (PG) BACKBONE | BIO SYNTHESIS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4658280-A2 | SIX MEMBERED RING CONTAINING OLIGOMERS | Alnylam Pharmaceuticals, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250346623-A1 | VERSATILE SYNTHETIC ROUTE FOR NEUTRAL MORPHOLINO OLIGONUCLEOTIDES WITH PHOSPHORYL GUANIDINIUM (PG) BACKBONE | BIO SYNTHESIS INC (US) | 2025-11-13 | — | — | US | disclosed |
| WO-2025236011-A1 | COMPOSITIONS FOR PHOSPHOROUS-AZOLE EXCHANGE CHEMISTRY AND USE THEREOF TO TARGET FUNCTIONAL PROTEIN SITES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250333433-A1 | REAGENTS AND METHODS FOR THE HIGHLY-EFFICIENT SYNTHESIS AND PURIFICATION OF BIOPOLYMERS | OLIGO FOUNDRY INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250313590-A1 | Phosphoramidite morpholino monomers towards synthesis/convergent synthesis of PMO, TMO, their chimera oligos in 5 prime to 3 prime direction | INDIAN ASSOCIATION FOR THE CULTIVATION OF SCIENCE (IACS) (IN) | 2025-10-09 | — | — | US | disclosed |
| US-20250290069-A1 | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2025-09-18 | — | — | US | disclosed |
| US-12414961-B2 | Substituted nucleosides and nucleotides for treating viral infections | EMORY UNIVERSITY (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250281519-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS, COMBINATIONS AND USES RELATED THERETO | EMORY UNIVERSITY | 2025-09-11 | — | — | US | disclosed |
| US-20250276988-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | SAREPTA THERAPEUTICS, INC. (US) | 2025-09-04 | — | — | US | disclosed |
| US-12383536-B2 | CRF receptor antagonists and methods of use | NEUROCRINE BIOSCIENCES, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-12377150-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-12378267-B2 | Synthesis of FMOC-protected morpholino monomers and oligomers | ENTRADA THERAPEUTICS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-4591935-A2 | METHODS FOR THE PREPARATION OF RIBOSIDES | Gilead Sciences, Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| EP-4588928-A2 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| WO-2025151707-A1 | METHOD FOR PREPARING MULTIMERS OF PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | ENTRADA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-2025122986-A1 | REAGENTS AND METHODS FOR THE HIGHLY-EFFICIENT SYNTHESIS AND PURIFICATION OF BIOPOLYMERS | Oligo Foundry, Inc. (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20250179487-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250171475-A1 | CHIRAL REAGENTS FOR PREPARATION OF HOMOGENEOUS OLIGOMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-05-29 | — | — | US | disclosed |
| US-20250171475-A1 | CHIRAL REAGENTS FOR PREPARATION OF HOMOGENEOUS OLIGOMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-05-29 | — | — | US | disclosed |
| US-12297219-B2 | Phosphorodiamidate morpholino oligomers | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12258362-B2 | Processes for preparing phosphorodiamidate morpholino oligomers | SAREPTA THERAPEUTICS, INC. | 2025-03-25 | — | — | US | disclosed |
| EP-4036099-B1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES INC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250064959-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| US-12221459-B2 | Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides | MEDIVIR AB (SE) | 2025-02-11 | — | — | US | disclosed |
| US-20250043283-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS VIA FAST-FLOW SYNTHESIS | SAREPTA THERAPEUTICS, INC. | 2025-02-06 | — | — | US | disclosed |
| US-12168674-B1 | Reagents and methods for the highly-efficient synthesis and purification of biopolymers | Oligo Foundry, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240400590-A1 | SYNTHESIS OF BACKBONE MODIFIED MORPHOLINO OLIGONUCLEOTIDES AND CHIMERAS USING PHOSPHORAMIDITE CHEMISTRY | UNIV COLORADO REGENTS (US) | 2024-12-05 | — | — | US | disclosed |
| CN-118974098-A | Multispecific binding agents and uses thereof | 埃克塞里艾克西斯公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2024233354-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240344067-A1 | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2024-10-17 | — | — | US | disclosed |
| US-12084468-B2 | Synthesis of backbone modified morpholino oligonucleotides and chimeras using phosphoramidite chemistry | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240287123-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2024-08-29 | — | — | US | disclosed |
| EP-3464305-B1 | PROCESSES FOR PREPARING OLIGOMERS | SAREPTA THERAPEUTICS INC (US) | 2024-08-21 | — | — | EP | disclosed |
| WO-2024163762-A2 | SIX MEMBERED RING CONTAINING OLIGOMERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-08-08 | — | — | WO | disclosed |
| EP-4406600-A2 | PROCESS FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | Sarepta Therapeutics, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| EP-4039690-B1 | A SUBSTANTIALLY DIASTEREOMERICALLY PURE PHOSPHORAMIDOCHLORIDATE, A METHOD AND A PHARMACEUTICAL COMPOSITION | EISAI R&D MAN CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| EP-4039690-C0 | A SUBSTANTIALLY DIASTEREOMERICALLY PURE PHOSPHORAMIDOCHLORIDATE, A METHOD AND A PHARMACEUTICAL COMPOSITION | EISAI R&D MAN CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| EP-4039690-B1 | A SUBSTANTIALLY DIASTEREOMERICALLY PURE PHOSPHORAMIDOCHLORIDATE, A METHOD AND A PHARMACEUTICAL COMPOSITION | EISAI R&D MAN CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-12012427-B2 | Synthesis of Fmoc-protected morpholino monomers and their use in the synthesis of morpholino oligomer | INDIAN ASSOCIATION FOR THE CULTIVATION OF SCIENCE (IN) | 2024-06-18 | — | — | US | disclosed |
| US-12012427-B2 | Synthesis of Fmoc-protected morpholino monomers and their use in the synthesis of morpholino oligomer | INDIAN ASSOCIATION FOR THE CULTIVATION OF SCIENCE (IN) | 2024-06-18 | — | — | US | disclosed |
| US-20240180948-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY | 2024-06-06 | — | — | US | disclosed |
| US-20240173345-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING SUBSTITUTED NUCLEOTIDE AND NUCLEOSIDE FOR TREATING VIRAL INFECTIONS | EMORY UNIVERSITY | 2024-05-30 | — | — | US | disclosed |
| US-20240165143-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY | 2024-05-23 | — | — | US | disclosed |
| WO-2024086592-A2 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNVERSITY (US) | 2024-04-25 | — | — | WO | disclosed |
| EP-4351581-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUES | Victoria Link Limited (NZ) | 2024-04-17 | — | — | EP | disclosed |
| EP-4122497-B1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS INC (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-3464306-B1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | SAREPTA THERAPEUTICS INC (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-4333859-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS, COMBINATIONS AND USES RELATED THERETO | Emory University (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20240042049-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| CN-110753755-B | T cell depletion state specific gene expression regulator and application thereof | 丹娜法伯癌症研究院 | 2023-12-29 | — | — | CN | disclosed |
| US-20230381216-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-11773126-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Pharmaceuticals, Inc. (US) | 2023-10-03 | — | — | US | disclosed |
| EP-3672601-B1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS VIA FAST-FLOW SYNTHESIS | SAREPTA THERAPEUTICS INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-11732259-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| EP-4219717-A2 | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY | Sarepta Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230212212-A1 | PROCESSES FOR PREPARING OLIGONUCLEOTIDES | SHANGHAI STA PHARMACEUTICAL R&D CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
| JP-2023085402-A | CHIRAL REAGENTS FOR PREPARATION OF HOMOGENEOUS OLIGOMERS | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2023-06-20 | — | — | JP | disclosed |
| US-20230172961-A1 | THERAPEUTICS FOR COVID-19 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-06-08 | — | — | US | disclosed |
| EP-4182315-A1 | PROCESSES FOR PREPARING OLIGONUCLEOTIDES | Changzhou Syntheall Pharmaceuticals Co., Ltd. (CN) | 2023-05-24 | — | — | EP | disclosed |
| US-11642364-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230110479-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230097585-A1 | SYNTHESIS OF FMOC-PROTECTED MORPHOLINO MONOMERS AND OLIGOMERS | ENTRADA THERAPEUTICS, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20230062181-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY | 2023-03-02 | — | — | US | disclosed |
| US-20230045831-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | SAREPTA THERAPEUTICS, INC. (US) | 2023-02-16 | — | — | US | disclosed |
| WO-2022174179-A9 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20230027727-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| EP-4122497-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | Sarepta Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-4115908-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | Sarepta Therapeutics, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20220409592-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2022-12-29 | — | — | US | disclosed |
| WO-2022260535-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2022-12-15 | — | — | WO | disclosed |
| US-20220387601-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| EP-4094767-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | Emory University (US) | 2022-11-30 | — | — | EP | disclosed |
| US-20220364084-A1 | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | US | disclosed |
| EP-4088718-A1 | METHODS FOR TREATING CORONAVIRIDAE VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| US-20220354873-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES, INC. | 2022-11-10 | — | — | US | disclosed |
| US-11492353-B2 | Methods and compounds for treating Paramyxoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-11491238-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220340605-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | SAREPTA THERAPEUTICS, INC. (US) | 2022-10-27 | — | — | US | disclosed |
| CN-113754694-B | Method for synthesizing Reidesvir by asymmetric catalysis of non-protecting group nucleoside | 上海交通大学 | 2022-10-25 | — | — | CN | disclosed |
| CN-113754694-B | Method for synthesizing Reidesvir by asymmetric catalysis of non-protecting group nucleoside | 上海交通大学 | 2022-10-25 | — | — | CN | disclosed |
| US-11472824-B2 | Processes for preparing phosphorodiamidate morpholino oligomers | SAREPTA THERAPEUTICS, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-20220296626-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY | 2022-09-22 | — | — | US | disclosed |
| US-20220280546-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| EP-3554554-B1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS INC (US) | 2022-09-07 | — | — | EP | disclosed |
| CN-115010657-A | Method for preparing 2-chloro-5-methylpyridine by continuous flow | 江苏瑞祥化工有限公司 | 2022-09-06 | — | — | CN | disclosed |
| WO-2022174194-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2022-08-18 | — | — | WO | disclosed |
| WO-2022174179-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2022-08-18 | — | — | WO | disclosed |
| EP-4040965-A2 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | Emory University (US) | 2022-08-17 | — | — | EP | disclosed |
| EP-3554552-B1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS INC (US) | 2022-08-17 | — | — | EP | disclosed |
| US-20220251551-A1 | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | US | disclosed |
| EP-4039690-A1 | A SUBSTANTIALLY DIASTEREOMERICALLY PURE PHOSPHORAMIDOCHLORIDATE, A METHOD AND A PHARMACEUTICAL COMPOSITION | Eisai R&D Management Co., Ltd. (JP) | 2022-08-10 | — | — | EP | disclosed |
| EP-4039690-A1 | A SUBSTANTIALLY DIASTEREOMERICALLY PURE PHOSPHORAMIDOCHLORIDATE, A METHOD AND A PHARMACEUTICAL COMPOSITION | Eisai R&D Management Co., Ltd. (JP) | 2022-08-10 | — | — | EP | disclosed |
| EP-4039690-A1 | A SUBSTANTIALLY DIASTEREOMERICALLY PURE PHOSPHORAMIDOCHLORIDATE, A METHOD AND A PHARMACEUTICAL COMPOSITION | Eisai R&D Management Co., Ltd. (JP) | 2022-08-10 | — | — | EP | disclosed |
| CN-114867351-A | 4' -halo-containing nucleotide and nucleoside therapeutic compositions and uses related thereto | 埃默里大学 | 2022-08-05 | — | — | CN | disclosed |
| EP-4034111-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | Neurocrine Biosciences, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-4036099-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | Gilead Sciences, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| US-11395855-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| EP-3554553-B1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS INC (US) | 2022-07-20 | — | — | EP | disclosed |
| US-11382981-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11384105-B2 | Processes for preparing oligomers | SAREPTA THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11382926-B2 | Methods for treating Arenaviridae and Coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11344565-B2 | Methods for the preparation of ribosides | GILEAD SCIENCES, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-11338041-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| CN-114502162-A | CRF receptor antagonists and methods of use | 纽罗克里生物科学有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20220144867-A1 | SYNTHESIS OF BACKBONE MODIFIED MORPHOLINO OLIGONUCLEOTIDES AND CHIMERAS USING PHOSPHORAMIDITE CHEMISTRY | UNIV COLORADO REGENTS (US) | 2022-05-12 | — | — | US | disclosed |
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | SAREPTA THERAPEUTICS INC (US) | 2022-04-28 | — | — | US | disclosed |
| EP-3043803-B1 | NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND THEIR USES | UNIV EMORY (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20220112491-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | SAREPTA THERAPEUTICS, INC. | 2022-04-14 | — | — | US | disclosed |
| EP-3349758-B1 | METHODS FOR TREATING ARENAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-114191438-A | Methods of treating filoviridae virus infections | 吉利德科学公司 | 2022-03-18 | — | — | CN | disclosed |
| US-11266666-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| US-11267844-B2 | Spirothietane nucleosides | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-08 | — | — | US | disclosed |
| US-20220048912-A1 | CYCLOBUTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-17 | — | — | US | disclosed |
| US-20220033406-A1 | CYCLOPENTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | Janssen Pharmaceuticals, Inc. | 2022-02-03 | — | — | US | disclosed |
| US-11230565-B2 | Synthesis of backbone modified morpholino oligonucleotides and chimeras using phosphoramidite chemistry | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2022-01-25 | — | — | US | disclosed |
| US-20220017901-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2022-01-20 | — | — | US | disclosed |
| US-11225662-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| WO-2022006871-A1 | PROCESSES FOR PREPARING OLIGONUCLEOTIDES | CHANGZHOU SYNTHEALL PHARMACEUTICALS CO., LTD. (CN) | 2022-01-13 | — | — | WO | disclosed |
| EP-3785717-B1 | METHODS FOR TREATING CORONAVIRIDAE INFECTIONS | GILEAD SCIENCES INC (US) | 2022-01-05 | — | — | EP | disclosed |
| US-11208655-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| CN-107073005-B | Methods of treating filoviridae virus infections | 吉利德科学公司 | 2021-12-24 | — | — | CN | disclosed |
| US-20210393659-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2021-12-23 | — | — | US | disclosed |
| US-20210395288-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | JANSSSEN BIOPHARMA, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| EP-3331891-B1 | A METHOD FOR PREPARING A SUBSTANTIALLY DIASTEREOMERICALLY PURE PHOSPHORODIAMIDATE OLIGOMER, A PHOSPHORODIAMIDATE OLIGOMER MADE BY SUCH A METHOD AND A PHARMACEUTICAL COMPOSITION COMPRISING SUCH A PHOSPHORODIAMIDATE OLIGOMER | EISAI R&D MAN CO LTD (JP) | 2021-12-15 | — | — | EP | disclosed |
| EP-3676276-B1 | SPIROTHIETANE NUCLEOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-08 | — | — | EP | disclosed |
| CN-113754694-A | Method for synthesizing Reidesvir by asymmetric catalysis of non-protecting group nucleoside | 上海交通大学 | 2021-12-07 | — | — | CN | disclosed |
| CN-113754694-A | Method for synthesizing Reidesvir by asymmetric catalysis of non-protecting group nucleoside | 上海交通大学 | 2021-12-07 | — | — | CN | disclosed |
| US-11192914-B2 | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto | EMORY UNIVERSITY (US) | 2021-12-07 | — | — | US | disclosed |
| EP-3212175-B1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES INC (US) | 2021-11-24 | — | — | EP | disclosed |
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210338830-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | US | disclosed |
| EP-3894394-A1 | CYCLOBUTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | Janssen BioPharma, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| EP-3894395-A2 | CYCLOPENTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | Janssen BioPharma, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| US-11149049-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20210308168-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-07 | — | — | US | disclosed |
| CN-113402715-A | Novel phosphorus-nitrogen flame retardant and preparation method thereof | 江苏集萃先进高分子材料研究所有限公司 | 2021-09-17 | — | — | CN | disclosed |
| WO-2021155119-A2 | THERAPEUTICS FOR COVID-19 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021137913-A2 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2021-07-08 | — | — | WO | disclosed |
| US-20210198296-A1 | PROCESSES FOR PREPARING OLIGOMERS | SAREPTA THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-20210171555-A1 | CHIRAL REAGENTS FOR PREPARATION OF HOMOGENEOUS OLIGOMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-06-10 | — | — | US | disclosed |
| US-20210169919-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-11021501-B2 | Creatine phosphate analog prodrugs, compositions and methods of use thereof | Farmington Pharma Development (US) | 2021-06-01 | — | — | US | disclosed |
| EP-2909222-B1 | 2',4'-BRIDGED NUCLEOSIDES FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-11007208-B2 | Methods for treating arenaviridae and coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20210139897-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | SAREPTA THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
| US-20210139524-A1 | SPIROTHIETANE NUCLEOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-13 | — | — | US | disclosed |
| US-20210138079-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| US-20210138078-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| US-20210139896-A1 | Peptide Oligonucleotide Conjugates | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2021-05-13 | — | — | US | disclosed |
| EP-2852603-B1 | D-AMINO ACID COMPOUNDS FOR LIVER DISEASE | IDENIX PHARMACEUTICALS LLC (US) | 2021-05-12 | — | — | EP | disclosed |
| US-11000600-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2021-05-11 | — | — | US | disclosed |
| US-20210130379-A1 | SYNTHESIS OF FMOC-PROTECTED MORPHOLINO MONOMERS AND THEIR USE IN THE SYNTHESIS OF MORPHOLINO OLIGOMER | INDIAN ASSOCIATION FOR THE CULTIVATION OF SCIENCE (IN) | 2021-05-06 | — | — | US | disclosed |
| US-20210130379-A1 | SYNTHESIS OF FMOC-PROTECTED MORPHOLINO MONOMERS AND THEIR USE IN THE SYNTHESIS OF MORPHOLINO OLIGOMER | INDIAN ASSOCIATION FOR THE CULTIVATION OF SCIENCE (IN) | 2021-05-06 | — | — | US | disclosed |
| WO-2021062246-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| US-10961262-B2 | Processes for preparing phosphorodiamidate morpholino oligomers | SAREPTA THERAPEUTICS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20210077628-A2 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPY | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2021-03-18 | — | — | US | disclosed |
| US-10947533-B2 | Processes for preparing phosphorodiamidate morpholino oligomers | SAREPTA THERAPEUTICS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20210061806-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2021-03-04 | — | — | US | disclosed |
| EP-3785717-A1 | METHODS FOR TREATING CORONAVIRIDAE INFECTIONS | Gilead Sciences, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| US-20210052613-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
| EP-3762394-A1 | CANCER TREATMENT WITH (2,2-BISHYDROXYMETHYL) METHYLENECYCLOPROPANE NUCLEOTIDES | Medivir Aktiebolag (SE) | 2021-01-13 | — | — | EP | disclosed |
| EP-3762372-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | Emory University (US) | 2021-01-13 | — | — | EP | disclosed |
| US-10888578-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-10875880-B2 | Processes for preparing oligomers | SAREPTA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200399295-A1 | CANCER TREATMENT WITH (2,2-BISHYDROXYMETHYL) METHYLENECYCLOPROPANE NUCLEOTIDES | MEDIVIR AB (SE) | 2020-12-24 | — | — | US | disclosed |
| CN-112074506-A | 4' -halo-containing nucleotide and nucleoside therapeutic compositions and uses related thereto | 埃默里大学 | 2020-12-11 | — | — | CN | disclosed |
| US-20200377886-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2020-12-03 | — | — | US | disclosed |
| US-20200362339-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS VIA FAST-FLOW SYNTHESIS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2020-11-19 | — | — | US | disclosed |
| EP-3738969-A1 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES FOR USE IN TREATING PNEUMOVIRINAE VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| US-10836784-B2 | Substituted phosphorodiamidate morpholino oligomers | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-11-17 | — | — | US | disclosed |
| US-20200352967-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2020-11-12 | — | — | US | disclosed |
| US-10765760-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200277598-A1 | Peptide Oligonucleotide Conjugates | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-09-03 | — | — | US | disclosed |
| US-20200277321-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2020-09-03 | — | — | US | disclosed |
| US-10758629-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10760078-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3695844-A1 | METHODS FOR TREATING NIPAH VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3684782-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen BioPharma, Inc. (US) | 2020-07-29 | — | — | EP | disclosed |
| US-10723754-B2 | 2′,4′-bridged nucleosides for HCV infection | IDENIX PHARMACEUTICALS LLC (US) | 2020-07-28 | — | — | US | disclosed |
| US-10717758-B2 | D-amino acid compounds for liver disease | IDENIX PHARMACEUTICALS LLC (US) | 2020-07-21 | — | — | US | disclosed |
| EP-3676276-A1 | SPIROTHIETANE NUCLEOSIDES | Janssen Pharmaceutica NV (BE) | 2020-07-08 | — | — | EP | disclosed |
| EP-3672601-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS VIA FAST-FLOW SYNTHESIS | Sarepta Therapeutics, Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| US-10696679-B2 | Methods and compounds for treating paramyxoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10695357-B2 | Methods for treating filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10695361-B2 | Methods for treating arenaviridae and coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20200197422-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200190516-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPY | SAREPTA THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| WO-2020121123-A2 | CYCLOPENTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | Janssen Biopharma, Inc. (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020121122-A1 | CYCLOBUTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | Janssen Biopharma, Inc. (US) | 2020-06-18 | — | — | WO | disclosed |
| EP-3183261-B1 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES | GILEAD SCIENCES INC (US) | 2020-06-17 | — | — | EP | disclosed |
| US-20200157137-A1 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200115405-A1 | CHIRAL REAGENTS FOR PREPARATION OF SUBSTITUTED PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-04-16 | — | — | US | disclosed |
| US-20200115709-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-04-16 | — | — | US | disclosed |
| US-20200087337-A1 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES | GILEAD SCIENCES, INC. | 2020-03-19 | — | — | US | disclosed |
| US-20200080079-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-03-12 | — | — | US | disclosed |
| US-20200078465-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPFA THERAPEUTICS INC (US) | 2020-03-12 | — | — | US | disclosed |
| US-20200040020-A1 | PROCESSES FOR PREPARING OLIGOMERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-02-06 | — | — | US | disclosed |
| WO-2019237297-A1 | PROCESSES FOR PREPARING COMPOUNDS/INTERMEDIATES USEFUL IN THE TREATMENT OF VIRAL INFECTIONS | Janssen Pharmaceuticals, Inc. (US) | 2019-12-19 | — | — | WO | disclosed |
| US-20190337971-A1 | PANTETHEINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGIC DISORDERS | Retrophin, Inc. | 2019-11-07 | — | — | US | disclosed |
| EP-3564248-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | Sarepta Therapeutics, Inc. (US) | 2019-11-06 | — | — | EP | disclosed |
| US-10457698-B2 | Chiral reagents for preparation of substituted phosphorodiamidate morpholino oligomers | EISAI R&D MANAGEMENT CO., LTD (JP) | 2019-10-29 | — | — | US | disclosed |
| EP-3554552-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | Sarepta Therapeutics, Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-3554553-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | Sarepta Therapeutics, Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-3554554-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | Sarepta Therapeutics, Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2019-10-03 | — | — | US | disclosed |
| US-20190292208-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | SAREPTA THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | US | disclosed |
| WO-2019173602-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2019-09-12 | — | — | WO | disclosed |
| WO-2019172835-A1 | CANCER TREATMENT WITH (2,2-BISHYDROXYMETHYL) METHYLENECYCLOPROPANE NUCLEOTIDES | MEDIVIR AKTIEBOLAG (SE) | 2019-09-12 | — | — | WO | disclosed |
| US-20190275063-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2019-09-12 | — | — | US | disclosed |
| US-20190276480-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-09-12 | — | — | US | disclosed |
| US-20190275072-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ETEPLIRSEN | SAREPTA THERAPEUTICS, INC. | 2019-09-12 | — | — | US | disclosed |
| US-20190255085-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2019-08-22 | — | — | US | disclosed |
| EP-3515445-A1 | SYNTHESIS OF BACKBONE MODIFIED MORPHOLINO OLIGONUCLEOTIDES AND CHIMERAS USING PHOSPHORAMIDITE CHEMISTRY | The Regents of The University of Colorado, A Body Corporate (US) | 2019-07-31 | — | — | EP | disclosed |
| US-20190218236-A1 | SYNTHESIS OF BACKBONE MODIFIED MORPHOLINO OLIGONUCLEOTIDES AND CHIMERAS USING PHOSPHORAMIDITE CHEMISTRY | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2019-07-18 | — | — | US | disclosed |
| US-20190218551-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-07-18 | — | — | US | disclosed |
| US-10344281-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190202852-A1 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES | GILEAD SCIENCES, INC. | 2019-07-04 | — | — | US | disclosed |
| US-10328089-B2 | Fumagillol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-25 | — | — | US | disclosed |
| EP-3487863-A1 | PANTETHEINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGIC DISORDERS | Retrophin, Inc. (US) | 2019-05-29 | — | — | EP | disclosed |
| EP-3252066-B1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2019-05-22 | — | — | EP | disclosed |
| US-20190144484-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY | 2019-05-16 | — | — | US | disclosed |
| CN-109641923-A | For treating the pantetheine derivative of neurological disease | 雷特罗芬公司 | 2019-04-16 | — | — | CN | disclosed |
| EP-3464305-A1 | PROCESSES FOR PREPARING OLIGOMERS | Sarepta Therapeutics, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-3463389-A2 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | Sarepta Therapeutics, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-3464306-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | Sarepta Therapeutics, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-3463363-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | Sarepta Therapeutics, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| US-10251904-B2 | Methods for treating arenaviridae and coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-10251898-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| WO-2019060862-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS VIA FAST-FLOW SYNTHESIS | SAREPTA THERAPEUTICS, INC. (US) | 2019-03-28 | — | — | WO | disclosed |
| WO-2019059973-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2019-03-28 | — | — | WO | disclosed |
| WO-2019053696-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-20190085013-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2019-03-21 | — | — | US | disclosed |
| US-20190085010-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2019-03-21 | — | — | US | disclosed |
| WO-2019043177-A1 | SPIROTHIETANE NUCLEOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-07 | — | — | WO | disclosed |
| US-20190055251-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2019-02-21 | — | — | US | disclosed |
| US-10202602-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-10149859-B2 | Nucleotide and nucleoside therapeutic compositions and uses related thereto | EMORY UNIVERSITY (US) | 2018-12-11 | — | — | US | disclosed |
| US-20180340004-A1 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES | GILEAD SCIENCES, INC. | 2018-11-29 | — | — | US | disclosed |
| US-10118941-B2 | Methods for the preparation of diastereomerically pure phosphoramidate prodrugs | MEDIVIR AB (SE) | 2018-11-06 | — | — | US | disclosed |
| US-20180311263-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2018-11-01 | — | — | US | disclosed |
| EP-3233870-B1 | FUMAGILLOL DERIVATIVES | TAKEDA PHARMACEUTICALS CO (JP) | 2018-10-31 | — | — | EP | disclosed |
| US-10106571-B2 | HCV polymerase inhibitors | MEDIVIR AB (SE) | 2018-10-23 | — | — | US | disclosed |
| US-20180298383-A1 | Peptide Oligonucleotide Conjugates | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-10-18 | — | — | US | disclosed |
| US-20180271993-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2018-09-27 | — | — | US | disclosed |
| US-20180258130-A1 | D-AMINO ACID COMPOUNDS FOR LIVER DISEASE | IDENIX PHARMACEUTICALS LLC | 2018-09-13 | — | — | US | disclosed |
| US-10065958-B2 | Methods and compounds for treating Paramyxoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2018-09-04 | — | — | US | disclosed |
| EP-3366295-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| US-20180223278-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-08-09 | — | — | US | disclosed |
| US-20180222932-A1 | CHIRAL REAGENTS FOR PREPARATION OF HOMOGENEOUS OLIGOMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-08-09 | — | — | US | disclosed |
| EP-3349758-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| EP-2046964-B1 | TRANSDUCIBLE DELIVERY OF NUCLEIC ACIDS BY REVERSIBLE PHOSPHOTRIESTER CHARGE NEUTRALIZATION PROTECTING GROUPS | UNIV CALIFORNIA (US) | 2018-07-04 | — | — | EP | disclosed |
| US-20180177814-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-06-28 | — | — | US | disclosed |
| WO-2018118599-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018118627-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018118662-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180162896-A1 | Synthesis of Phosphoramidates | SANDOZ AG (CH) | 2018-06-14 | — | — | US | disclosed |
| EP-3331891-A2 | CHIRAL REAGENTS FOR PREPARATION OF HOMOGENEOUS OLIGOMERS | Eisai R&D Management Co., Ltd. (JP) | 2018-06-13 | — | — | EP | disclosed |
| US-9982006-B2 | 2′-chloro aminopyrimidinone and pyrimidine dione nucleosides | GILEAD SCIENCES, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3212174-B1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2018-05-16 | — | — | EP | disclosed |
| US-9949994-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20180105549-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2018-04-19 | — | — | US | disclosed |
| EP-3303360-A1 | SELECTIVE PROCESS FOR SYNTHESIS OF NUCLEOSIDE PHOSPHORAMIDATES | Sandoz AG (CH) | 2018-04-11 | — | — | EP | disclosed |
| WO-2018057430-A1 | SYNTHESIS OF BACKBONE MODIFIED MORPHOLINO OLIGONUCLEOTIDES AND CHIMERAS USING PHOSPHORAMIDITE CHEMISTRY | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2018-03-29 | — | — | WO | disclosed |
| US-20180050051-A1 | FUMAGILLOL DERIVATIVES | TAKEDA CALIFORNIA, INC. | 2018-02-22 | — | — | US | disclosed |
| WO-2018022529-A1 | PANTETHEINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGIC DISORDERS | Retrophin, Inc. (US) | 2018-02-01 | — | — | WO | disclosed |
| CN-107646037-A | Method for selectively synthesizing nucleoside phosphoramidate compound | 桑多斯股份公司 | 2018-01-30 | — | — | CN | disclosed |
| US-9862946-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| EP-3252066-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2017-12-06 | — | — | EP | disclosed |
| WO-2017205513-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | SAREPTA THERAPEUTICS, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017205880-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | SAREPTA THERAPEUTICS, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017205879-A2 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | SAREPTA THERAPEUTICS, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017205496-A1 | PROCESSES FOR PREPARING OLIGOMERS | SAREPTA THERAPEUTICS, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-9828408-B2 | HCV polymerase inhibitors | MEDIVIR AB (SE) | 2017-11-28 | — | — | US | disclosed |
| US-9827255-B2 | Fumagillol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-28 | — | — | US | disclosed |
| US-20170327526-A1 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES | GILEAD SCIENCES, INC. | 2017-11-16 | — | — | US | disclosed |
| WO-2017189978-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2017-11-02 | — | — | WO | disclosed |
| EP-3233870-A1 | FUMAGILLOL DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2017-10-25 | — | — | EP | disclosed |
| US-9790499-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170275322-A1 | METHODS FOR THE PREPARATION OF DIASTEREOMERICALLY PURE PHOSPHORAMIDATE PRODRUGS | MEDIVIR AB (SE) | 2017-09-28 | — | — | US | disclosed |
| CN-107207547-A | Fumagillol derivative | 武田药品工业株式会社 | 2017-09-26 | — | — | CN | disclosed |
| WO-2017155923-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2017-09-14 | — | — | WO | disclosed |
| EP-3212175-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | Gilead Sciences, Inc. (US) | 2017-09-06 | — | — | EP | disclosed |
| CN-107074826-A | Dioxolane analogues of uridine for the treatment of cancer | 美迪维尔公司 | 2017-08-18 | — | — | CN | disclosed |
| US-9724360-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| EP-3041855-B1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2017-07-26 | — | — | EP | disclosed |
| EP-3194414-A1 | METHODS FOR THE PREPARATION OF DIASTEREOMERICALLY PURE PHOSPHORAMIDATE PRODRUGS | MEDIVIR AB (SE) | 2017-07-26 | — | — | EP | disclosed |
| US-20170198287-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-07-13 | — | — | US | disclosed |
| EP-3183261-A1 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES | Gilead Sciences, Inc. (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9688707-B2 | Bicyclic morpholino compounds and oligomeric compounds prepared therefrom | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| WO-2017106710-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2017-06-22 | — | — | WO | disclosed |
| CN-104470939-B | D-amino acid compounds for liver diseases | 埃迪尼克斯医药有限责任公司 | 2017-04-26 | — | — | CN | disclosed |
| US-20170107244-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2017-04-20 | — | — | US | disclosed |
| US-9617295-B2 | 2′-chloro aminopyrimidinone and pyrimidine dione nucleosides | GILEAD SCIENCES, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| WO-2017049060-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-20170071964-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2017-03-16 | — | — | US | disclosed |
| WO-2017024264-A2 | CHIRAL REAGENTS FOR PREPARATION OF HOMOGENEOUS OLIGOMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-02-09 | — | — | WO | disclosed |
| US-9546364-B2 | Synthetic lariat RNA for RNA interference | CARNEGIE MELLON UNIVERSITY (US) | 2017-01-17 | — | — | US | disclosed |
| US-9540411-B2 | HCV polymerase inhibitors | MEDIVIR AB (SE) | 2017-01-10 | — | — | US | disclosed |
| US-20160376587-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-12-29 | — | — | US | disclosed |
| US-20160361330-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| WO-2016189040-A1 | SELECTIVE PROCESS FOR SYNTHESIS OF NUCLEOSIDE PHOSPHORAMIDATES | SANDOZ AG (CH) | 2016-12-01 | — | — | WO | disclosed |
| US-20160340380-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2016-11-24 | — | — | US | disclosed |
| EP-2483288-B1 | PHOSPHORAMIDATE DERIVATIVES OF NUCLEOSIDES | JANSSEN PRODUCTS LP (US) | 2016-11-16 | — | — | EP | disclosed |
| US-9481703-B2 | HCV polymerase inhibitors | MEDIVIR AB (SE) | 2016-11-01 | — | — | US | disclosed |
| US-9469664-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| WO-2016160885-A1 | CREATINE PHOSPHATE ANALOG PRODRUGS, COMPOSITIONS AND USES THEREOF | Farmington Pharma Development (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20160289253-A1 | CREATINE PHOSPHATE ANALOG PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | Farmington Pharma Development | 2016-10-06 | — | — | US | disclosed |
| CN-102686599-B | Phosphoramidate derivatives of nucleosides | 杨森产品有限公司 | 2016-10-05 | — | — | CN | disclosed |
| US-20160271160-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2016-09-22 | — | — | US | disclosed |
| WO-2016145142-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTICS COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2016-09-15 | — | — | WO | disclosed |
| EP-3057976-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2016-08-24 | — | — | EP | disclosed |
| US-20160237426-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-08-18 | — | — | US | disclosed |
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2016-08-04 | — | — | US | disclosed |
| EP-3043803-A1 | NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND USES RELATED THERETO | Emory University (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-3041855-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2016-07-13 | — | — | EP | disclosed |
| US-20160186175-A1 | BICYCLIC MORPHOLINO COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | IONIS PHARMACEUTICALS, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160186174-A1 | SUBSTITUTED MORPHOLINO COMPOUNDS ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | IONIS PHARMACEUTICALS, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160175332-A1 | FUMAGILLOL DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2016-06-23 | — | — | US | disclosed |
| WO-2016100778-A1 | FUMAGILLOL DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016069825-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES, INC. (US) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016069827-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2016-05-06 | — | — | WO | disclosed |
| US-20160122356-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES, INC. | 2016-05-05 | — | — | US | disclosed |
| US-20160122374-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2016-05-05 | — | — | US | disclosed |
| EP-2336141-B1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | THRESHOLD PHARMACEUTICALS INC (US) | 2016-03-30 | — | — | EP | disclosed |
| WO-2016041877-A1 | METHODS FOR THE PREPARATION OF DIASTEREOMERICALLY PURE PHOSPHORAMIDATE PRODRUGS | MEDIVIR AB (SE) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016035006-A1 | NOVEL NUCLEOTIDE ANALOGS, PROCESS FOR THE PREPARATION OF SOFOSBUVIR AND ITS ANALOGS, NOVEL FORMS OF SOFOSBUVIR AND SOLID DISPERSION OF SOFOSBUVIR | DR. REDDY’S LABORATORIES LIMITED (IN) | 2016-03-10 | — | — | WO | disclosed |
| US-9278987-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20160052953-A1 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES | GILEAD SCIENCES, INC. | 2016-02-25 | — | — | US | disclosed |
| WO-2016028866-A1 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES | GILEAD SCIENCES, INC. (US) | 2016-02-25 | — | — | WO | disclosed |
| US-20160002281-A1 | D-AMINO ACID COMPOUNDS FOR LIVER DISEASE | UNIVERSITE DE MONTPELLIER (FR) | 2016-01-07 | — | — | US | disclosed |
| US-9226932-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9211300-B2 | 4′-fluoro nucleosides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2015-12-15 | — | — | US | disclosed |
| EP-2935304-A1 | 4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX Pharmaceuticals, Inc. (US) | 2015-10-28 | — | — | EP | disclosed |
| US-9161948-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9156874-B2 | Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs | NANJING MOLECULAR RESEARCH, INC. (CN) | 2015-10-13 | — | — | US | disclosed |
| EP-1774331-B1 | CYTOXAN ANTIBODIES AND IMMUNOASSAY | SALADAX BIOMEDICAL INC (US) | 2015-09-02 | — | — | EP | disclosed |
| EP-2909222-A1 | 2',4'-BRIDGED NUCLEOSIDES FOR HCV INFECTION | IDENIX Pharmaceuticals, Inc. (US) | 2015-08-26 | — | — | EP | disclosed |
| CN-102256991-B | Uracyl cyclopropyl nucleotides | CENTOCOR ORTHO BIOTECH PRODUCT (US) | 2015-08-12 | — | — | CN | disclosed |
| US-9095599-B2 | O-(substituted benzyl) phosphoramidate compounds and therapeutic use | NANJING MOLECULAR RESEARCH, INC. (CN) | 2015-08-04 | — | — | US | disclosed |
| CN-102153607-B | Water soluble camptothecin derivative and medicinal composition containing same | HUNAN FANGSHENG HUAMEI MEDICAL TECHNOLOGY CO LTD | 2015-07-15 | — | — | CN | disclosed |
| US-20150175648-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-06-25 | — | — | US | disclosed |
| US-20150152116-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2015-06-04 | — | — | US | disclosed |
| WO-2015056213-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-04-23 | — | — | WO | disclosed |
| US-20150111839-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2015-04-23 | — | — | US | disclosed |
| EP-2852603-A1 | D-AMINO ACID COMPOUNDS FOR LIVER DISEASE | IDENIX Pharmaceuticals, Inc. (US) | 2015-04-01 | — | — | EP | disclosed |
| CN-104470939-A | D-amino acid compounds for liver diseases | IDENIX PHARMACEUTICALS INC | 2015-03-25 | — | — | CN | disclosed |
| WO-2015038596-A1 | NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2015-03-19 | — | — | WO | disclosed |
| US-20150073140-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | SAREPTA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| WO-2015034420-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-03-12 | — | — | WO | disclosed |
| US-8906609-B1 | Label-free biomolecule sensor based on surface charge modulated ionic conductance | ARROWHEAD CENTER, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140330006-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | SAREPTA THERAPEUTICS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140309413-A1 | METHODS OF STEREOSELECTIVE SYNTHESIS OF SUBSTITUTED NUCLEOSIDE ANALOGS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-16 | — | — | US | disclosed |
| WO-2014164533-A1 | METHODS OF STEREOSELECTIVE SYNTHESIS OF SUBSTITUTED NUCLEOSIDE ANALOGS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-09 | — | — | WO | disclosed |
| US-8846638-B2 | Macrocyclic nucleoside phosphoramidate derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140286903-A1 | Substituted Purine Nucleosides, Phosphoramidate and Phosphordiamidate Derivatives for Treatment if Viral Infections | INHIBITEX, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| EP-2780299-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | Sarepta Therapeutics, Inc. (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20140273216-A1 | Synthetic Lariat RNA for RNA Interference | Camegie Mellon University (US) | 2014-09-18 | — | — | US | disclosed |
| EP-2776438-A1 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHORAMIDATE AND PHOSPHORDIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | Inhibitex, Inc. (US) | 2014-09-17 | — | — | EP | disclosed |
| EP-2373671-B1 | URACYL CYCLOPROPYL NUCLEOTIDES | JANSSEN PRODUCTS LP (US) | 2014-09-10 | — | — | EP | disclosed |
| EP-2595980-B1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2014-09-03 | — | — | EP | disclosed |
| WO-2014124430-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2014-08-14 | — | — | WO | disclosed |
| US-8779128-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140178338-A1 | 4'-FLUORO NUCLOSIDES FOR THE TREATMENT OF HCV | UNIVERSITE DE MONTPELLIER (FR) | 2014-06-26 | — | — | US | disclosed |
| WO-2014099941-A1 | 4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140170240-A1 | Phosphoramidate Alkylator Prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| WO-2014066239-A1 | 2',4'-BRIDGED NUCLEOSIDES FOR HCV INFECTION | IDENIX PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | WO | disclosed |
| US-20140112887-A1 | 2',4'-BRIDGED NUCLEOSIDES FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC | 2014-04-24 | — | — | US | disclosed |
| EP-2704749-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | Sarepta Therapeutics, Inc. (US) | 2014-03-12 | — | — | EP | disclosed |
| US-20140066398-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR, AB (SE) | 2014-03-06 | — | — | US | disclosed |
| US-8664204-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664195-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20140038916-A1 | O-(SUBSTITUTED BENZYL) PHOSPHORAMIDATE COMPOUNDS AND THERAPEUTIC USE | NANJING MOLECULAR RESEARCH, INC. (CN) | 2014-02-06 | — | — | US | disclosed |
| US-8623912-B2 | Fostriecin derivatives and the pharmaceutical uses thereof | BEIJING BIOSTAR TECHNOLOGIES, LTD. (CN) | 2014-01-07 | — | — | US | disclosed |
| WO-2013187978-A1 | DOUBLE-LIVER-TARGETING PHOSPHORAMIDATE AND PHOSPHONOAMIDATE PRODRUGS | NANJING MOLECULAR RESEARCH, INC. (CN) | 2013-12-19 | — | — | WO | disclosed |
| WO-2013177219-A1 | D-AMINO ACID COMPOUNDS FOR LIVER DISEASE | IDENIX PHARMACEUTICALS, INC. (US) | 2013-11-28 | — | — | WO | disclosed |
| US-20130315864-A1 | MACROCYCLIC NUCLEOSIDE PHOSPHORAMIDATE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-20130315868-A1 | D-AMINO ACID COMPOUNDS FOR LIVER DISEASE | IDENIX PHARMACEUTICALS, INC. | 2013-11-28 | — | — | US | disclosed |
| WO-2013173759-A2 | MACROCYCLIC NUCLEOSIDE PHOSPHORAMIDATE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | WO | disclosed |
| US-20130303778-A1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | THRESHOLD PHARMACEUTICALS, INC. | 2013-11-14 | — | — | US | disclosed |
| US-8552021-B2 | Phosphoramidate derivatives of nucleosides | JANSSEN PRODUCTS, L.P. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20130210757-A1 | DOUBLE-LIVER-TARGETING PHOSPHORAMIDATE AND PHOSPHONOAMIDATE PRODRUGS | NANJING MOLECULAR RESEARCH, INC. (CN) | 2013-08-15 | — | — | US | disclosed |
| US-8507464-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| WO-2013084165-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2013-06-13 | — | — | WO | disclosed |
| US-20130143835-A1 | HCV Polymerase Inhibitors | MEDIVIR AB (SE) | 2013-06-06 | — | — | US | disclosed |
| EP-2595980-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2013-05-29 | — | — | EP | disclosed |
| WO-2013074834-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | SAREPTA THERAPEUTICS, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013070887-A1 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHORAMIDATE AND PHOSPHORDIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | INHIBITEX, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| EP-2576574-A2 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | Sarepta Therapeutics, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| US-8399429-B2 | Uracyl cyclopropyl nucleotides | JANSSEN PRODUCTS, LP (US) | 2013-03-19 | — | — | US | disclosed |
| US-8324378-B2 | Prodrugs and conjugates of prenylation inhibitors | PURDUE RESEARCH FOUNDATION (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120289457-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | AVI BIOPHARMA, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| WO-2012150960-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | AVI BIOPHARMA, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
| US-8299206-B2 | Method of synthesis of morpholino oligomers | AVI BIOPHARMA, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| CN-102686599-A | Phosphoramidate derivatives of nucleosides | JANSSEN PRODUCTS LP | 2012-09-19 | — | — | CN | disclosed |
| US-20120225839-A1 | Phosphoramidate Derivatives of Nucleosides | MEDIVIR AB | 2012-09-06 | — | — | US | disclosed |
| EP-2483288-A2 | PHOSPHORAMIDATE DERIVATIVES OF NUCLEOSIDES | Janssen Products, L.P. (US) | 2012-08-08 | — | — | EP | disclosed |
| WO-2012094248-A1 | O-(SUBSTITUTED BENZYL) PHOSPHORAMIDATE COMPOUNDS AND THERAPEUTIC USE | NANJING MOLECULAR RESEARCH, INC. (CN) | 2012-07-12 | — | — | WO | disclosed |
| US-20120093729-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2012-03-15 | — | — | US | disclosed |
| US-20120065171-A1 | FOSTRIECIN DERIVATIVES AND THE PHARMACEUTICAL USES THEREOF | DALIAN UNIVERSITY OF TECHNOLOGY (CN) | 2012-03-15 | — | — | US | disclosed |
| US-20120027752-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2012012776-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| US-8080536-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8076476-B2 | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits | AVI BIOPHARMA, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076476-B2 | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits | AVI BIOPHARMA, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| WO-2011150408-A2 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | AVI BIOPHARMA, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| CN-102256991-A | Uracyl cyclopropyl nucleotides | CENTOCOR ORTHO BIOTECH PRODUCT | 2011-11-23 | — | — | CN | disclosed |
| US-20110251159-A1 | Phosphoramidate Alkylator Prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| EP-2373671-A1 | URACYL CYCLOPROPYL NUCLEOTIDES | Centocor Ortho Biotech Products L.P. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20110230436-A1 | Uracyl Cyclopropyl Nucleotides | CENTOCOR ORTHO BIOTECH PRODUCTS L.P. (US) | 2011-09-22 | — | — | US | disclosed |
| US-8003625-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| CN-102153607-A | Water soluble camptothecin derivative and medicinal composition containing same | HUNAN FANGSHENG HUAMEI MEDICAL TECHNOLOGY CO LTD | 2011-08-17 | — | — | CN | disclosed |
| EP-2336141-A2 | Phosphoramidate alkylator prodrugs | Threshold Pharmaceuticals, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2011039221-A2 | PHOSPHORAMIDATE DERIVATIVES OF NUCLEOSIDES | CENTOCOR ORTHO BIOTECH PRODUCTS L.P. (US) | 2011-04-07 | — | — | WO | disclosed |
| US-20110009356-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| EP-2272838-A1 | FOSTRIECIN DERIVATIVES AND THE PHARMACEUTICAL USES THEREOF | Baygen Pharm Technology Co., Ltd. (CN) | 2011-01-12 | — | — | EP | disclosed |
| US-20100331397-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-7816345-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| CN-101861318-A | Method of synthesis of morpholino oligomers | AVI BIOPHARMA INC | 2010-10-13 | — | — | CN | disclosed |
| US-20100249072-A1 | PRODRUGS AND CONJUGATES OF PRENYLATION INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2010-09-30 | — | — | US | disclosed |
| EP-2207779-A1 | METHOD OF SYNTHESIS OF MORPHOLINO OLIGOMERS | Avi Biopharma, Inc. (US) | 2010-07-21 | — | — | EP | disclosed |
| EP-2207779-A1 | METHOD OF SYNTHESIS OF MORPHOLINO OLIGOMERS | Avi Biopharma, Inc. (US) | 2010-07-21 | — | — | EP | disclosed |
| WO-2010066699-A1 | URACYL CYCLOPROPYL NUCLEOTIDES | CENTOCOR ORTHO BIOTECH PRODUCTS L.P. (US) | 2010-06-17 | — | — | WO | disclosed |
| US-20100137254-A1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | IMMUNOGENESIS, INC. | 2010-06-03 | — | — | US | disclosed |
| EP-2166016-A1 | Phosphoramidate Derivatives of Nucleosides | Centocor Ortho Biotech Products L.P. (US) | 2010-03-24 | — | — | EP | disclosed |
| WO-2009064471-A1 | METHOD OF SYNTHESIS OF MORPHOLINO OLIGOMERS | AVI BIOPHARMA, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064471-A1 | METHOD OF SYNTHESIS OF MORPHOLINO OLIGOMERS | AVI BIOPHARMA, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131632-A1 | METHOD OF SYNTHESIS OF MORPHOLINO OLIGOMERS | AVI BIOPHARMA, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131624-A1 | SYNTHESIS OF MORPHOLINO OLIGOMERS USING DOUBLY PROTECTED GUANINE MORPHOLINO SUBUNITS | AVI BIOPHARMA, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131624-A1 | SYNTHESIS OF MORPHOLINO OLIGOMERS USING DOUBLY PROTECTED GUANINE MORPHOLINO SUBUNITS | AVI BIOPHARMA, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| EP-2046964-A2 | TRANSDUCIBLE DELIVERY OF NUCLEIC ACIDS BY REVERSIBLE PHOSPHOTRIESTER CHARGE NEUTRALIZATION PROTECTING GROUPS | The Regents of the University of California (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20090093425-A1 | TRANSDUCIBLE DELIVERY OF NUCLEIC ACIDS BY REVERSIBLE PHOSPHOTRIESTER CHARGE NEUTRALIZATION PROTECTING GROUPS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2009029849-A1 | PRODRUGS AND CONJUGATES OF PRENYLATION INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20080125605-A1 | Novel Phosphorus-Containing Prodrugs | METABASIS THERAPEUTICS, INC. | 2008-05-29 | — | — | US | disclosed |
| EP-1896040-A2 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | Threshold Pharmaceuticals, Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1774331-A4 | CYTOXAN ANTIBODIES AND IMMUNOASSAY | SALADAX BIOMEDICAL INC (US) | 2008-02-13 | — | — | EP | disclosed |
| US-7326695-B2 | Anti-bacterial agents based upon oxoanion binding | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2008-02-05 | — | — | US | disclosed |
| WO-2008008476-A2 | TRANSDUCIBLE DELIVERY OF NUCLEIC ACIDS BY REVERSIBLE PHOSPHOTRIESTER CHARGE NEUTRALIZATION PROTECTING GROUPS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20070249564-A1 | Novel phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2007-10-25 | — | — | US | disclosed |
| US-7276347-B2 | Cytoxan antibodies and immunoassay | SALADAX BIOMEDICAL INC. (US) | 2007-10-02 | — | — | US | disclosed |
| EP-1774331-A2 | CYTOXAN ANTIBODIES AND IMMUNOASSAY | Saladax Biomedical Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| US-7205404-B1 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-20070054883-A1 | Anti-bacterial agents based upon oxoanion binding | THE TRUSTEES OF PRINCETON UNIVERSITY | 2007-03-08 | — | — | US | disclosed |
| EP-1165570-B9 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2007-02-21 | — | — | EP | disclosed |
| US-7173020-B2 | Phosphoramidates and methods therefor | PURDUE RESEARCH FOUNDATION (US) | 2007-02-06 | — | — | US | disclosed |
| WO-2007002931-A2 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| EP-1724276-A1 | Novel phosphorus-containing prodrugs | Metabasis Therapeutics, Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1165570-B1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2006-08-23 | — | — | EP | disclosed |
| US-7074776-B2 | Anti-bacterial agents based upon oxoanion binding | QUOREX PHARMACEUTICALS, INC. (US) | 2006-07-11 | — | — | US | disclosed |
| WO-2006037090-A2 | DRUG-PHOSPHATE CONJUGATES AS PRODRUGS | PURDUE RESEARCH FOUNDATION (US) | 2006-04-06 | — | — | WO | disclosed |
| EP-1634886-A2 | Novel phosphorus-containing prodrug | Metabasis Therapeutics, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2006020263-A2 | CYTOXAN ANTIBODIES AND IMMUNOASSAY | SALADAX BIOMEDICAL INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| EP-1268493-B1 | PHOSPHORAMIDATE PRODRUGS | PURDUE RESEARCH FOUNDATION (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20060024752-A1 | Cytoxan antibodies and immunoassay | SALADAX BIOMEDICAL INC. | 2006-02-02 | — | — | US | disclosed |
| US-20060024748-A1 | Cytoxan antibodies and immunoassay | SALADAX BIOMEDICAL INC. | 2006-02-02 | — | — | US | disclosed |
| EP-0506830-B1 | UNCHARGED MORPHOLINO-BASED POLYMERS HAVING PHOSPHOROUS-CONTAINING CHIRAL INTERSUBUNIT LINKAGES | AVI BIOPHARMA INC (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050171060-A1 | Phosphoramidates and methods therefor | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-08-04 | — | — | US | disclosed |
| US-20050123533-A1 | Prodrugs activated by targeted catalytic proteins | WELLSTAT BIOCATALYSIS, LLC | 2005-06-09 | — | — | US | disclosed |
| US-6903081-B2 | Phosphoramidates and methods therefor | PURDUE RESEARCH FOUNDATION (US) | 2005-06-07 | — | — | US | disclosed |
| EP-1418923-A4 | ANTI-BACTERIAL AGENTS BASED UPON OXOANION BINDING | QUOREX PHARMACEUTICALS INC (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20040152669-A1 | Anti-bacterial agents based upon oxoanion binding | PRINCETON UNIVERSITY, THE TRUSTEES OF | 2004-08-05 | — | — | US | disclosed |
| EP-1418923-A1 | ANTI-BACTERIAL AGENTS BASED UPON OXOANION BINDING | Quorex Pharmaceuticals, Inc. (US) | 2004-05-19 | — | — | EP | disclosed |
| US-6737415-B2 | EXPOSING BACTERIUM TO CYCLIC BORATE, PHOSPHATE, SULFATE, AMIDE COMPOUNDS FOR CONTROLLING BACTERIAL GROWTH | QUOREX PHARMACEUTICALS, INC. | 2004-05-18 | — | — | US | disclosed |
| US-20030105062-A1 | Anti-bacterial agents based upon oxoanion binding | PRINCETON UNIVERSITY, THE TRUSTEES OF | 2003-06-05 | — | — | US | disclosed |
| US-20030096765-A1 | Prodrugs activated by targeted catalytic proteins | IGEN, INC. | 2003-05-22 | — | — | US | disclosed |
| WO-2003018029-A1 | ANTI-BACTERIAL AGENTS BASED UPON OXOANION BINDING | QUOREX PHARMACEUTICALS, INC. (US) | 2003-03-06 | — | — | WO | disclosed |
| EP-1268493-A1 | PHOSPHORAMIDATE PRODRUGS | PURDUE RESEARCH FOUNDATION (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020004594-A1 | Phosphoramidates and methods therefor | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-01-10 | — | — | US | disclosed |
| EP-1165570-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | Metabasis Therapeutics, Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001074827-A1 | PHOSPHORAMIDATE PRODRUGS | PURDUE RESEARCH FOUNDATION (US) | 2001-10-11 | — | — | WO | disclosed |
| WO-2000052015-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| US-RE35524-E | Epipodophyllotoxin glucoside 4'-phosphate derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-06-03 | — | — | US | disclosed |
| EP-0746336-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0746336-A4 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN INC (US) | 1996-07-26 | — | — | EP | disclosed |
| US-5521063-A | Polynucleotide reagent containing chiral subunits and methods of use | ANTIVIRALS INC. (US) | 1996-05-28 | — | — | US | disclosed |
| US-5407537-A | Preheating alkenylsuccinic anhydride, mixing with water, injecting under pressure into cellulose/water slurry treated with cationizing agent, forming web, drying | EXXON CHEMICAL PATENTS INC (US) | 1995-04-18 | — | — | US | disclosed |
| US-5378841-A | Alpha-morpholino ribonucleoside derivatives and polymers thereof | ANTIVIRALS INC. (US) | 1995-01-03 | — | — | US | disclosed |
| US-5334741-A | Contacting surface of substrate with phosphoramidate solution, heating to thermolyse and generate metaphosphate which phosphorylates substrate | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1994-08-02 | — | — | US | disclosed |
| EP-0369762-B1 | Pesticides | ROUSSEL UCLAF (FR) | 1993-12-29 | — | — | EP | disclosed |
| US-5235033-A | ALPHA-MORPHOLINO RIBONUCLEOSIDE DERIVATIVES AND POLYMERS THEREOF | ANTI-GENE DEVELOPMENT GROUP (US) | 1993-08-10 | — | — | US | disclosed |
| WO-1993002703-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1993-02-18 | — | — | WO | disclosed |
| US-5187266-A | Cytotoxic, viricidal | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) | 1993-02-16 | — | — | US | disclosed |
| US-5185444-A | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages | ANTI-GENE DEVEOPMENT GROUP (US) | 1993-02-09 | — | — | US | disclosed |
| EP-0506830-A4 | UNCHARGED MORPHOLINO-BASED POLYMERS HAVING PHOSPHOROUS-CONTAINING CHIRAL INTERSUBUNIT LINKAGES | — | 1993-01-07 | — | — | EP | disclosed |
| EP-0512046-A1 | PROCESS FOR SIZING PAPER AND SIMILAR PRODUCTS | Callaway Chemical Company (US) | 1992-11-11 | — | — | EP | disclosed |
| EP-0506830-A1 | UNCHARGED MORPHOLINO-BASED POLYMERS HAVING PHOSPHOROUS-CONTAINING CHIRAL INTERSUBUNIT LINKAGES | ANTIVIRALS INC. (US) | 1992-10-07 | — | — | EP | disclosed |
| US-5114538-A | Treating cellulose fibers with cationic papermaking stock adding a reactive sizing agent, forming a web and reacting the size | EXXON CHEMICAL PATENTS INC. (US) | 1992-05-19 | — | — | US | disclosed |
| EP-0483130-A1 | NOVEL ANTITUMOR ALDOPHOSPHAMIDE ANALOGS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1992-05-06 | — | — | EP | disclosed |
| US-5091552-A | Novel antitumor aldophosphamide analogs | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1992-02-25 | — | — | US | disclosed |
| US-5055459-A | Purging leukemic tumor cells from mammals | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS (US) | 1991-10-08 | — | — | US | disclosed |
| US-5041424-A | Antitumor agents | BRISTOL-MYERS COMPANY (US) | 1991-08-20 | — | — | US | disclosed |
| WO-1991010777-A1 | PROCESS FOR SIZING PAPER AND SIMILAR PRODUCTS | EXXON CHEMICAL PATENTS INC. (US) | 1991-07-25 | — | — | WO | disclosed |
| WO-1991009033-A1 | UNCHARGED MORPHOLINO-BASED POLYMERS HAVING PHOSPHOROUS-CONTAINING CHIRAL INTERSUBUNIT LINKAGES | ANTI-GENE DEVELOPMENT GROUP (US) | 1991-06-27 | — | — | WO | disclosed |
| WO-1990010636-A1 | NOVEL ANTITUMOR ALDOPHOSPHAMIDE ANALOGS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1990-09-20 | — | — | WO | disclosed |
| US-4904768-A | Epipodophyllotoxin glucoside 4'-phosphate derivatives | BRISTOL-MYERS COMPANY (US) | 1990-02-27 | — | — | US | disclosed |
| EP-0348127-A2 | Process for sizing paper and similar products | EXXON CHEMICAL PATENTS INC. (US) | 1989-12-27 | — | — | EP | disclosed |
| JP-H01238594-A | POLYSACCHARIDES AND MACROMOLECULAR CONJUGATES THEREOF | AMERICAN CYANAMID CO | 1989-09-22 | — | — | JP | disclosed |
| EP-0228222-A2 | Pesticidal dihalovinylalkenylamides | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-07-08 | — | — | EP | disclosed |
| US-3937765-A | REACTING A PHENOL AND A N,N-DIALKYL PHOSPHOAMIDIC HALIDE | STAUFFER CHEMICAL COMPANY (US) | 1976-02-10 | — | — | US | disclosed |
| US-3937765-A | REACTING A PHENOL AND A N,N-DIALKYL PHOSPHOAMIDIC HALIDE | STAUFFER CHEMICAL COMPANY (US) | 1976-02-10 | — | — | US | disclosed |